Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (RNAC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rnac · stock forecast · 10 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$25.00
Consensus
$20.50
+249.8% upside
Low
$16.00
Median: $20.5 · Last Close: $5.86
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$20.50
249.8% upside
High Target
$25
326.6%
Low Target
$16
173.0%
Current Price
$5.86
as of today
Based on analyst price targets, the RNAC stock price prediction for the next 12 months ranges from $16 to $25. The consensus RNAC price forecast of $20.50 implies 249.8% upside from the current price of $5.86.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.57 | ↓ 5.00% |
1-day model range: $5.4–$5.73. Peak: $5.73 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · RNAC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-27 | Wedbush | Maintains | Outperform→Outperform |
| 2026-05-26 | Needham | Maintains | Buy→Buy |
| 2026-05-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-01 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-10 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-09 | Cantor Fitzgerald | Upgrade ↑ | Neutral→Overweight |
| 2026-03-09 | Needham | Maintains | Buy→Buy |
| 2026-01-09 | Needham | Maintains | Buy→Buy |
| 2025-11-19 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-11-14 | BTIG | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Cartesian Therapeutics, Inc. (RNAC) stock. Of the recent 64 rating actions, 3 were upgrades and 4 were downgrades. 10 analysts currently cover RNAC.
Analyst Recommendation Trends
RNAC analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 4 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 97.7% YoY
Revenue Next Year
$0M
↓ 16.5% YoY
EPS This Year
$-4.15
EPS Next Year
$-3.83
↓ 7.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RNAC EPS of $-4.15 for the current fiscal year, based on estimates from 4 analysts. The RNAC revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RNAC stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RNAC price target is $20.50 (+249.8% upside), with an analyst consensus of Buy.
The RNAC short-term stock prediction for tomorrow is $5.57 (-5.00%). The RNAC stock prediction for 2030 projects a range of $2–$2.
Cartesian Therapeutics, Inc. trades on NASDAQ under the ticker RNAC. The RNAC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 80% of covering analysts.
Frequently asked questions
RNAC forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month RNAC price target is $20.50, with a high forecast of $25.00 and a low of $16.00. The median price target is shown in the chart above when available. This implies +249.8% potential upside from the current price of $5.86.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.